Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Jardiance

- PMLiVE

Lilly gets FDA approval for severe alopecia areata treatment for paediatric patients

Treatment with Olumiant resulted in substantial scalp hair regrowth, as well as improvements in eyebrows and eyelashes

- PMLiVE

Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal

The deal focuses on addressing critical unmet medical needs

- PMLiVE

Lilly to acquire Merida Biosciences in deal worth up to $2.875bn

The acquisition is to advance treatments for serious autoimmune and allergic diseases

- PMLiVE

Eli Lilly’s Foundayo authorised by UK MHRA for weight loss and type 2 diabetes

The UK is the first country in Europe to authorise the oral medication

- PMLiVE

Lilly’s olomorasib gets FDA Breakthrough Therapy designation for pancreatic cancer

Around 60,000 people in the US get pancreatic cancer each year, with an estimated 50,000 deaths projected annually

- PMLiVE

Lilly to acquire AtaiBeckley in deal worth $2.8bn

The acquisition will advance therapies for treatment-resistant depression and other mental health conditions

- PMLiVE

Boehringer Ingelheim’s Jascayd approved by MHRA for idiopathic pulmonary fibrosis

This is the first treatment breakthrough in pulmonary fibrosis in over a decade

- PMLiVE

Oxford BioTherapeutics announces clinical milestones from its collaboration with Boehringer Ingelheim

The collaboration began in 2013 and was later expanded in 2020 and 2023

- PMLiVE

Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis

This new option for patients allows for as few as six maintenance injections per year

- PMLiVE

Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn

The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease

- PMLiVE

Lilly and UNICEF collaborate to improve non-communicable disease prevention

Six-year initiative to improve NCD prevention and care for children in low- and middle-income countries

- PMLiVE

Boehringer and Immunitas agree on licensing deal for chronic inflammatory and autoimmune diseases

The agreement strengthens Boehringer Ingelheim’s growing immunology pipeline

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links